title: Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles.
abstract: Comparison of human leukocyte antigen (HLA) frequencies in patients with hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) and in patients with HCV-associated non-Hodgkin's lymphoma (NHL) has not been addressed previously. To this aim, we investigated the distribution of HLA class II alleles in two selected groups of HCV-infected patients. Group 1 included 50 patients with HCV-associated NHL; group 2 included 29 patients with HCV-associated HCC. A control group included 144 hospitalized patients without NHL or HCC and who were negative for HCV, hepatitis B virus, and human immunodeficiency virus antibodies. Polymerase chain reaction sequence DRB1 and DQB1 specific-primer methods were used. DRB1*1101/DQB1*0301 haplotype, which mainly favors the spontaneous clearance of HCV infection, was lower in HCC subjects than in controls, whereas HLA-DRB1*1104/DQB1*0301, was higher in NHL patients. These findings suggest different pathogenic pathways in HCC and in NHL development. In patients with HCV-associated HCC, a major protective role of DQB1*0301 allele, rather than DRB1*11, was found, probably because of a better HLA class II-associated virus clearance. By contrast, the same allele as HLA-DRB1*04 showed an increase in HCV-associated NHL. These data suggest that NHL and HCC development may be associated to a different response with respect to chronic HLA class II-restricted antigen presentation (perhaps a switch toward CD4+Th2 response in NHL?) or, alternatively, that these alleles could be in linkage disequilibrium to unrelated gene(s), or are in synergy with other immunomodulatory genes that may confer increased risk for NHL.
authors.affiliation: Division of Experimental Oncology Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, Italy. vdere@cro.it
authors.forename: V
authors.initials: V
authors.lastname: De Re
authors.forename: L
authors.initials: L
authors.lastname: Caggiari
authors.forename: R
authors.initials: R
authors.lastname: Talamini
authors.forename: M
authors.initials: M
authors.lastname: Crovatto
authors.forename: S
authors.initials: S
authors.lastname: De Vita
authors.forename: C
authors.initials: C
authors.lastname: Mazzaro
authors.forename: R
authors.initials: R
authors.lastname: Cannizzaro
authors.forename: R
authors.initials: R
authors.lastname: Dolcetti
authors.forename: M
authors.initials: M
authors.lastname: Boiocchi
mesh_terms: D000483:Alleles; D006528:Carcinoma, Hepatocellular / Q000209:etiology* / Q000235:genetics; D005787:Gene Frequency; D005802:Genes, MHC Class II / Q000235:genetics*; D005838:Genotype; D006683:HLA-DQ Antigens / Q000235:genetics; D059866:HLA-DQ beta-Chains; D006684:HLA-DR Antigens / Q000235:genetics; D059811:HLA-DRB1 Chains; D006239:Haplotypes / Q000235:genetics; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008113:Liver Neoplasms / Q000209:etiology* / Q000235:genetics; D016393:Lymphoma, B-Cell / Q000209:etiology* / Q000235:genetics; D012307:Risk Factors
chemical_list: D006683:HLA-DQ Antigens; D059866:HLA-DQ beta-Chains; C069051:HLA-DQB1 antigen; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains